leisure time -WSS

leisure time

author：hotspot 2025-10-02 20:47:35 - browse：6264

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Peter Hotez and the public health issue of online harassment
Next article： #NeedHerScience: shining a light on gender disparities in medicine

WSS

Death of patient in Alzheimer’s trial raises question of possible risks

Headspace, Meta partner to launch VR meditation app for Quest

Change Healthcare cyberattack prompts Medicare loan program

UnitedHealth quietly bought dozens of outpatient centers

3 hurdles to bringing medical devices to the U.S. market

Cloning humans is technically possible. It's curious no one has tried

hotspot

leisure time

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

The story of mRNA: From a loose idea to a tool that may help curb Covid

In age of alternative facts, a scholarly course on calling out crap

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Malaria cases in Florida and Texas: Here’s what you need to know

Novo Nordisk obesity pill bests Wegovy in early trial

Virginia high school admissions case could be legal follow

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Guidelines to prevent youth baseball injuries need more muscle

UnitedHealth quietly bought dozens of outpatient centers

hotspot

With psoriasis trial ahead, Alumis raises $259 million

What would happen to your eyes if you looked at the solar eclipse?

Donald Trump's relentless attacks on special counsel Jack Smith

Do masks work? RCTs can't tell us

Why we need to separate burnout from moral injury in health care

Colonoscopy at 40? Study finds a possible benefit

Wikipedia

explore

hotspot

focus